Seroatlas · Human Serome Atlas

ADO

2-aminoethanethiol dioxygenase

Also known as: AEDO_HUMAN, C10orf22, FLJ14547

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96SZ5
Gene: ADO
Ensembl: ENSG00000181915
Chromosome: 10
Canonical length: 270 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins

OverviewNCBI Gene

Human thiol dioxygenases include cysteine dioxygenase (CDO; MIM 603943) and cysteamine (2-aminoethanethiol) dioxygenase (ADO; EC 1.13.11.19). CDO adds 2 oxygen atoms to free cysteine, whereas ADO adds 2 oxygen atoms to free cysteamine to form hypotaurine (Dominy et al., 2007 [PubMed 17581819]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

270 residues, UniProt reviewed canonical sequence.

>Q96SZ5|ADO
     1  MPRDNMASLI QRIARQACLT FRGSGGGRGA SDRDAASGPE APMQPGFPEN LSKLKSLLTQ
    61  LRAEDLNIAP RKATLQPLPP NLPPVTYMHI YETDGFSLGV FLLKSGTSIP LHDHPGMHGM
   121  LKVLYGTVRI SCMDKLDAGG GQRPRALPPE QQFEPPLQPR EREAVRPGVL RSRAEYTEAS
   181  GPCILTPHRD NLHQIDAVEG PAAFLDILAP PYDPDDGRDC HYYRVLEPVR PKEASSSACD
   241  LPREVWLLET PQADDFWCEG EPYPGPKVFP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 35 nTPM

Expression across tissuesHPA

Tissue

testis: 35 nTPM
spinal cord: 34 nTPM
tongue: 16 nTPM
cerebral cortex: 16 nTPM
midbrain: 14 nTPM
heart muscle: 14 nTPM

Single-cell type

late spermatids: 525 nCPM
late primary spermatocytes: 249 nCPM
early spermatids: 161 nCPM
peritubular myoid cells: 30 nCPM
gastric progenitor cells: 23 nCPM
respiratory ionocytes: 20 nCPM

Immune cell

intermediate monocyte: 1.3 nTPM
memory B-cell: 1.3 nTPM
myeloid DC: 0.9 nTPM
non-classical monocyte: 0.9 nTPM
basophil: 0.8 nTPM
classical monocyte: 0.8 nTPM

Brain region

white matter: 53 nTPM
cerebellum: 39 nTPM
medulla oblongata: 37 nTPM
spinal cord: 35 nTPM
midbrain: 32 nTPM
basal ganglia: 32 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.81
gnomAD pLI: 0.48
gnomAD missense Z: 1.61
DepMap mean gene effect: -0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

cellular response to hypoxia

Molecular functions

iron ion binding
cysteamine dioxygenase activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

RmlC-like cupin domain superfamily
RmlC-like jelly roll fold
Cysteine oxygenase/2-aminoethanethiol dioxygenase
PCO_ADO

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADO as an antibody target. Whether an autoantibody or antibody against ADO could matter depends on whether native ADO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADO is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ADO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...